ABSTRACT Mucus hyper-secretion is a hallmark feature of asthma and other muco-obstructive airway diseases. The mucin proteins MUC5AC and MUC5B are the major glycoprotein components of mucus and have critical roles in airway defense. Despite the biomedical importance of these two proteins, the loci that regulate them in the context of natural genetic variation have not been studied. To identify genes that underlie variation in airway mucin levels, we performed genetic analyses in founder strains and incipient lines of the Collaborative Cross (CC) in a house dust mite mouse model of asthma. CC founder strains exhibited significant differences in MUC5AC and MUC5B, providing evidence of heritability. Analysis of gene and protein expression of Muc5ac and Muc5b in incipient CC lines (n = 154) suggested that post-transcriptional events were important regulators of mucin protein content in the airways. Quantitative trait locus (QTL) mapping identified distinct, trans protein QTL for MUC5AC (chromosome 13) and MUC5B (chromosome 2). These two QTL explained 18 and 20% of phenotypic variance, respectively. Examination of the MUC5B QTL allele effects and subsequent phylogenetic analysis allowed us to narrow the MUC5B QTL and identify Bpifb1 as a candidate gene. Bpifb1 mRNA and protein expression were upregulated in parallel to MUC5B after allergen challenge, and Bpifb1 knockout mice exhibited higher MUC5B expression. Thus, BPIFB1 is a novel regulator of MUC5B.
MUC5B is significantly elevated in COPD and CF (Fahy and Dickey 2010) , as well as idiopathic pulmonary fibrosis (IPF) (Seibold et al. 2011) , and is the primary mucin in plugs removed from the lungs after fatal status asthmaticus (Sheehan et al. 1995; Groneberg et al. 2002) . In addition to associations with disease, MUC5B regulates features of lung homeostasis, such as mucociliary clearance, suggesting it has a critical role in lung defense to pathogens (Roy et al. 2013) .
While there has been a great deal of research on the biochemical pathways that regulate mucin genes and corresponding proteins (Rose and Voynow 2006; Davis and Dickey 2008; Thai et al. 2008) , the genetic architecture of mucus phenotypes in both humans and animal models is not well characterized. Previous studies provided evidence that the chronic mucus hyper-secretion phenotype in COPD (also known as chronic bronchitis) has a familial component (Viegi et al. 1994; Silverman et al. 1998) , and results from a twin study indicated that 40% of variation in the chronic mucus hyper-secretion phenotype is attributable to genetic variation (Hallberg et al. 2008 ). Genome-wide association studies have identified two SNPs (rs6577641 in SATB1 and rs34391416 near the genes EFCAB4A, CHID1, and AP2A2) associated with chronic mucus hyper-secretion in the context of COPD (Dijkstra et al. 2014; Lee et al. 2014) , but these loci do not explain a large fraction of the estimated heritability. This could in part be due to the need to rely on survey data to ascertain phenotype status in these studies, which dichotomizes the quantitative nature of muco-obstructive phenotypes and is subject to recall bias, resulting in reduced power to detect significant associations.
Given the importance of MUC5AC and MUC5B in mucoobstructive airway diseases, we sought to identify key regulators of these secreted mucins using an unbiased, genome-wide search. To accomplish this goal, we utilized incipient lines of the Collaborative Cross (CC). The CC is composed of a panel of recombinant inbred mouse lines derived from eight-way crosses using five classical inbred strains (C57BL/6J, 129S1/ SvImJ, A/J, NOD/ShiLtJ, and NZO/H1LtJ) and three wildderived inbred strains (WSB/EiJ, PWK/PhJ, and CAST/EiJ) (Collaborative Cross Consortium 2012). Studies with incipient and established CC lines have identified quantitative trait loci for numerous traits of biomedical interest (Aylor et al. 2011; Kelada et al. 2012 Kelada et al. , 2014 Rutledge et al. 2014; Gralinski et al. 2015; Mosedale et al. 2017; Venkatratnam et al. 2017) . Within this framework, we applied a house dust mite (HDM) model (Kelada et al. 2011) to elicit MUC5AC and MUC5B expression and secretion in mouse airways. We used quantitative protein measurements of secreted mucins, QTL mapping, gene expression, and genome sequence data to identify candidate regulators of these secreted mucins. Further, we interrogated the relationship between MUC5B and the candidate regulator Bpifb1 with gene and protein expression data, followed by the use of a knockout strain to validate BPIFB1 as a novel regulator of MUC5B in the airways.
Materials and Methods

Mice
We obtained 154 male pre-CC mice (ages 10-14 weeks) from Oak Ridge National Laboratory (Chesler et al. 2008) . Each mouse was from an independent CC line that had undergone 5-14 generations of inbreeding. We also obtained male mice of each of the eight CC founder strains from The Jackson Laboratory (n = 3-4/strain were phenotyped, plus additional C57BL/6J mice). All mice were singly housed, with alpha-dri bedding, under normal 12-hr light/dark cycles. All experiments conducted with mice in this study were compliant with an Institutional Animal Care and Use Committee protocol at an animal facility approved and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
To generate Bpifb1 KO mice, sperm from hemizygous male Bpifb1 mice was obtained from the Knockout Mouse Project (KOMP) (www.komp.org). These mice were created from embryonic stem cell clone EPD0704_3_A09 obtained from the KOMP Repository and generated by the Wellcome Trust Sanger Institute. Methods used on the targeted alleles have been published (Skarnes et al. 2011) . In this work, the Tm1a allele was used without subsequent modification or removal of cassette elements. Sperm was used to fertilize eggs from C57BL/6NJ mice, and heterozygous offspring were mated to generate a colony of mice used for the experiment.
Mice were genotyped using a single PCR reaction containing two different forward primers [wild-type (WT) allele primer: 59-GAAGAGGGAAGGTCAGGAGAAAGGG-39 and knockout (CSD-neoF) allele primer 59-GGGATCTCATGCTGGAGTTCT TCG-39] and one common reverse primer (59-TAAGGTCC TTTGGTCAACGGTTTGC-39). PCR products were analyzed by gel electrophoresis, with the WT allele producing a 535-bp product and the knockout allele producing a 646-bp product.
By and large, matings of heterozygous mice produced Mendelian ratios of offspring. However, in the third generation we observed transmission ratio distortion with a depletion of homozygous mutant pups (four born, nine expected), suggesting that either loss of Bpifb1 has some effect on genotype ratios that is incompletely penetrant or that an additional mutation on the strain background contributed to non-Mendelian ratios. This effect was not observed in three subsequent generations.
Homozygous WT and knockout littermates (males and females) were used in experiments in which mice were either used at baseline (i.e., naïve, no allergen exposure) or sensitized twice (i.p.) with 10 mg of Der p 1 and challenged with PBS or 50 mg of Der p 1. Within each genotype, mice were randomized to treatment groups.
Phenotyping protocol
We employed an HDM model of allergic airway disease that produces hallmark asthma phenotypes including T h 2-biased airway inflammation, elevated serum IgE, mucous cell metaplasia, and airway hyper-responsiveness in a strain-dependent fashion (Kelada et al. 2011) . Results for inflammatory cell recruitment [eosinophils (Kelada et al. 2014) and neutrophils ], responsiveness to methacholine (Kelada 2016) , and lung gene expression (eQTL) (Kelada et al. 2014) have been previously published. At the start of our study, mice were phenotyped by whole body plethysmography for baseline responsiveness to methacholine (on days 1 and 8). The mice were then sensitized with 10 mg (in 100 ml) of the immunodominant allergen from the Dermatophagoides pteronyssinus species of HDM, Der p 1 (Cat. No. LTN-DP1-1; Indoor Biotechnology), administered by intraperitoneal injection on days 11 and 18 of the protocol. On day 25, mice were challenged with 50 mg of Der p 1 (in 100 ml), administered by oro-pharyngeal aspiration. Mice were phenotyped for responsiveness to methacholine again by whole body plethysmography on day 28. Immediately following this measurement, mice were killed by an overdose of pentobarbitol, followed by collection of blood, whole lung lavage fluid, and lung tissue. Lung lavage was performed using two successive volumes of 0.5 and 1.0 ml PBS. The first fraction of lavage fluid was spun down (500 g for 10 min) to separate out cells and the supernatant was retained for analysis of mucins by agarose gel electrophoresis followed by immunoblotting.
Agarose gel electrophoresis and immunoblotting
We used a previously established method (Kirkham et al. 2002) involving agarose gel electrophoresis following by immunoblotting to detect MUC5AC and MUC5B in bronchoalveolar lavage fluid (BALF). Briefly, the addition of urea powder (40 mg/0.1 ml) to BALF produced a 6 M urea BALF, which was reduced with 10 mM dithiothreitol for 90 min and alkylated with 25 mM iodoacetamide to obtain constituent mucin monomer subunits. Equal volumes of reduced samples (40 ml) were run on 1% agarose gel. Gels were vacuum-blotted onto nitrocellulose membranes, blocked with Odyssey blocking buffer (LI-COR Biosciences), and probed with a rabbit polyclonal antibody (Ab) raised against murine MUC5AC or MUC5B (Ehre et al. 2012) [UNC294 and UNC222, respectively, generously provided by Dr. Camille Ehre (UNC)]. Using sequence data (Keane et al. 2011) , we determined that there were no missense variants encoded in Muc5ac or Muc5b at the epitopes recognized by these antibodies, thus each antibody-based measurement should have been unbiased with respect to strain. The secondary Ab was Alexa Fluor 680 goat anti-rabbit IgG, diluted 1/15,000 in Odyssey blocking buffer. Detection and analysis of specific signals were performed using the Odyssey CLx infrared imaging system (LI-COR Biosciences). For quantification, the integrated intensity of the major high-molecular-weight bands in each lane was measured by defining a rectangular region of interest (ROI) encompassing these bands in the sample with the strongest signal and using this ROI for all lanes (as shown in Supplemental Material, Figure S1 , Odyssey software version 3.0 or ImageStudio version 1.0.11). The median intensity of three pixels on the right and the left of the defined ROI was used to define the background, which was subtracted from the integrated intensity value. Owing to the large number of pre-CC samples, they had to be run on five different gels. To normalize the integrated intensity values for transfer efficiency and antibody binding, the same volume of two different positive control samples (BALF from C57BL/6N mice treated with IL-13) was loaded on each row of every gel (as illustrated in Figure S1 ), and their integrated intensity values were used to normalize the values for the pre-CC samples. BALF from Muc5ac KO and Muc5b KO mice were used as controls to confirm antibody specificity as reported in Livraghi-Butrico et al. (2017) . Phenotype data for CC founder strains and pre-CC mice are given in Table S1 and Table S2 , respectively.
For statistical analyses of pre-CC mice, MUC5AC and MUC5B intensity values were natural log-transformed. For MUC5AC, we observed a spike in the distribution at the low end of the range, suggesting that these values were near the limit of detection, and we removed these data points (n = 10 mice) from further analysis.
Heritability estimates
Analysis of variance was used to test whether phenotypes varied among CC founder strains. From these ANOVA models, we estimated broad-sense heritability (H 2 ) by calculating the interclass correlation (r 1 ) and the coefficient of genetic determination (g 2 ) (Festing 1979) :
where MSB and MSW are the mean squares between and within, respectively, from the eight-way ANOVA model described above and n is the number of mice per strain (n = 3-4/strain).
Genotyping, quantitative trait locus (QTL) mapping, and phylogeny
We genotyped each mouse at the University of North Carolina at Chapel Hill using one of two Affymetrix SNP arrays (A or B) that were produced during the development of the Mouse Diversity array (Yang et al. 2009 ), resulting in 27,059 mapping intervals, as described in a previous study . These genotyping arrays were annotated to NCBI Build 36 of the mouse genome, but we mapped QTL boundaries to Build 37 positions and we report Build 37 positions in our results. We used BAGPIPE (Valdar et al. 2009) to fit a regression model and report LOD scores for QTL mapping of mucin protein levels. For MUC5AC, QTL mapping was carried out using the data set after removal of values below the apparent threshold of detection. Inclusion of values below the threshold resulted in no significant QTL. Significance thresholds were determined by permutation (n = 10,000). We used the 1.5 LOD drop method to approximate confidence interval for QTL (Dupuis and Siegmund 1999) . The proportion of variance explained for each QTL was estimated by regression of phenotypes on genotype for the peak locus for each QTL. Allele effects plots were used to identify putative functional haplotype groupings using a previously established method (Kelada et al. 2012) . Post hoc statistical tests of these haplotypes were conducted using Tukey's honestly significant difference test. To build a phylogenetic tree relating the eight CC founder strains at the Chr 2 QTL, we generated sequence alignments using sequence data (http://www. sanger.ac.uk/sanger/Mouse_SnpViewer/rel-1211) (Keane et al. 2011 ) and then generated a maximum likelihood tree using RAxML version 7.2.9 (Stamatakis 2006) . One hundred bootstrap samples were used to assess the support for each tree branch. Please see File S1 for code used to run RAxML.
Candidate gene identification
To identify candidate genes for the MUC5B QTL on Chr 2, we applied a weight of evidence approach based on a series of criteria. This included the following criteria:
1. Evidence that the gene is expressed in airway epithelia, based on expression data from a previous study (GSE34764) (Doherty et al. 2012) . Specifically, we used samples from the control group (PBS, n = 3) of GSE34764 to characterize the distribution of gene expression and then categorized genes in the bottom fifth percentile as not expressed while genes above or equal to the fifth percentile were considered expressed. 2. Evidence that the gene is differentially expressed in whole lung RNA samples as a function of allergen treatment, based on a previous study we conducted (GSE19223) (Kelada et al. 2011) . For this criterion, we conducted an analysis of differential expression using Partek software (version 6.6) and used nominal P-values ,0.05 and fold change .1.5. 3. Evidence that the gene is differentially expressed in normal lung tissue as a function of Chr 2 founder haplotype, which was assessed using two independent gene expression data sets involving strains from different subspecies [A/J (musculus haplotype) and C57BL/6J (domesticus haplotype) in GSE30015 and WSB/EiJ (domesticus haplotype) and PWK/PhJ (musculus haplotype) in GSE44555] (Crowley et al. 2015) . This analysis was conducted using R (version 3.1.2) using the MAANOVA package after masking for probesets that contain variants from musculus haplotypes. For this criterion, we did not specify a fold change cutoff, only a nominal statistical significance threshold of ,0.05. However, we did specify that the direction of the gene expression difference (either higher or lower) be consistent across the two studies. 4. Unique sharing of nonsynonymous variants among the Chr 2 musculus haplotypes. We used sequence data (Keane et al. 2011 ) and a corresponding web query tool (http://www. sanger.ac.uk/sanger/Mouse_SnpViewer/rel-1211) to identify nonsynonymous variants that are shared by A/J, NOD/ ShiLtJ, and PWK/PhJ strains and not present in other CC founder strains. 5. Prior evidence of biological relevance. We conducted literature searches in PubMed and used the Mouse Genome Informatics website to find previously published evidence that a particular gene may be relevant to allergic airway inflammation and/or mucus production/secretion.
Gene expression by qRT-PCR
RNA from the right lung middle lobe was isolated using the RNEasy Kit (Qiagen, Valencia, CA) and reverse transcribed using the High Capacity RNA to cDNA kit (Applied Biosystems, Foster City, CA) according to manufacturers' protocols. TaqMan assays for Muc5b and Bpifb1 were custom designed to avoid genetic variants at these loci in the CC founder strain genomes. Assays were validated for efficient amplification using serial dilutions of template. Primer and probe pairs are as follows: Muc5b F: 59-AAGGTGTATGTACCAACTGG-39, R: 59-TGTAC TATCCTGGGTCCTC-39, Probe: 59-TGTGACCTCTCCTGTC CACCCAC-39; Bpifb1 F: 59-CACAAGCTCTCCTTCGTG-39, R: 59-TACATGTCATCAAAGGCCTG-39, Probe: 59-TGAATCTCCTG GTGCCAGCCCTG-39. DCt values were calculated by normalizing to Rps20 (Mm02342828_g1, Applied Biosystems). A two-sided or one-sided Student's t-test was used to analyze the data as noted, and a significant change was defined as a = 0.05.
Histology and immunohistochemistry
Formalin-fixed left lung lobes were cut in cross-section starting at the hilum and 2 mm apart along the main stem bronchus, yielding three slices/lung (level 1, 2, and 3 from rostral to caudal). All three slices were embedded in paraffin, and 5-mm-thick sections were cut and stained with AB-PAS. Immunohistochemistry for MUC5B and BPIFB1 was performed as previously described (Livraghi-Butrico et al. 2017) . Briefly, sections were incubated for 1 hr with FC Block (BD Pharmigen) at 1:200 in 5% normal goat serum (NGS) (JacksonImmuno) in phosphate buffered saline with 0.1% Tween-20 and for 3 hr with 1:1000 MUC5B (H-300, Santa Cruz Biotech) or 1:200 BPIFB1 (HP8044, Hycult Biotech) primary antibodies in 5% NGS. Rabbit IgG (JacksonImmuno) was used as isotype control for both antibodies. Goat anti-rabbit biotinylated secondary antibody (JacksonImmuno) was applied on all sections at 1:200 in 5% NGS for 30 min. The VECTSTAIN Elite ABC R.T.U and Immpact NovaRed horseradish peroxidase detection systems (Vector Laboratories, Burlingame, CA) were used according to the manufacturer's protocols. Slides were counterstained with Mayer's hematoxylin before dehydration and mounting with DPX (Sigma Aldrich). Slides were imaged on an Olympus BX60F5 microscope with CellSens Standard software (Olympus Life Sciences version 1.13).
Morphometric analysis
Total airway or luminal histological staining was quantified morphometrically on level 1 (the level most affected by mucous cell metaplasia and mucus accumulation) by investigators blind to treatment and genotype. Total, intraepithelial (stored), and luminal AB-PAS positive and MUC5B or BPIFB1-positive volume densities (Vs) were quantified using 103 or 203 magnification micrographs as previously described (Harkema et al. 1987) .
Meta-analysis of gene expression data
Eight gene expression data from mouse models of asthma were identified in NCBI's GEO database (GSE1301, GSE13032, GSE13382, GSE1438, GSE19223, GSE27066, GSE34764, and GSE6858). In all but one case (GSE1438), data were downloaded then normalized (using the default robust multi-array average with quantile normalization method) using Partek software (version 6.6). Statistical analysis of differential gene expression was also conducted in Partek, accounting for strain if .1 strain was included in the study. For GSE1438, we used NCBI's GEO2R web-based software to conduct data analysis because of the custom arrays used in that experiment. Meta-analysis of gene expression data from NCBI's GEO repository was conducted using Fisher's combined probability test.
Data availability
Supplemental Material is provided in File S1, a zip file containing perl scripts used in QTL mapping and code use for phylogenetic analysis. Phenotype data are provided in Table  S1 and Table S2 . Genotype calls for pre-CC mice are available at http://www.genetics.org/content/198/2/735.supplemental.
Results
To identify regulators of secreted MUC5AC and MUC5B in the airway, we applied an HDM model of asthma (Kelada et al. 2011) involving the immunodominant antigen Der p 1. In preliminary experiments using C57BL/6J mice, we quantified secreted MUC5AC and MUC5B levels in BALF after Der p 1 allergen sensitization and challenge using agarose gel electrophoresis followed by immunoblotting. These experiments revealed that the vast majority of MUC5AC and MUC5B were contained in the soluble fraction of BALF and that allergen treatment increased MUC5AC 10-fold and MUC5B 6-fold ( Figure S2 ). We then phenotyped CC founder strains for MUC5AC and MUC5B BALF levels after allergen sensitization and challenge, and we included a subset of A/J mice that were sensitized but challenged only with PBS (vehicle). As shown in Figure 1 , levels of MUC5AC and MUC5B in BALF varied significantly by strain. For both mucins, the effect of strain was greater than the effect of treatment alone in the A/J strain.
Estimates of broad-sense heritability for MUC5AC among allergen sensitized and challenged mice based on interclass correlations (r 1 ) and the coefficient of genetic determination (g 2 ) were 0.77 and 0.63, respectively. For MUC5B, the corresponding heritability estimates were 0.69 and 0.53. These results indicate that variation in the levels of both mucins is significantly associated with variation in the genome. We then phenotyped 154 incipient lines of the CC, which we refer to as "pre-CC" mice. Each pre-CC mouse was derived from a different CC breeding funnel and contained allelic contributions from all eight founder strains (Aylor et al. 2011) . Pre-CC mice were treated with Der p 1 allergen and exhibited a wide range of MUC5AC and MUC5B levels in BALF ( Figure S3 ). We examined pairwise correlations between MUC5AC and MUC5B and found a weak but statistically significant and positive correlation between the two mucin proteins ( Figure  S4 ; r = 0.25, P = 0.005), where the correlation was strongest toward the higher ranges of MUC5AC and MUC5B expression. In contrast, pairwise correlations of Muc5ac and Muc5b mRNA [assessed using previously generated data (Kelada et al. 2014) ] were quite strong ( Figure S4 ; r = 0.83, P , 1 3 10 24 ). Interestingly, pairwise correlations between each mucin mRNA and protein were weak or absent, suggesting post-transcriptional events that uncouple intracellular mRNA and secreted protein levels.
To identify the specific genetic loci that control mucin levels in response to allergen sensitization and challenge, we used the pre-CC phenotype and genotype data to map QTL for each mucin protein (Figure 2 ). For MUC5AC, we identified a QTL on Chr 13 (Muc5acq1, LOD = 7.2, Figure 2A) , spanning 71.6-81.0 Mb, and for MUC5B, we identified a QTL on Chr 2 (Muc5bq1, LOD = 7.9, Figure 2B ), spanning 152.5-159.8 Mb. These two QTL explained 18 and 20% of phenotype variation, respectively. The genes encoding both mucins are located on Chr 7, indicating these two pQTL act in trans, and the fact that the two trans-pQTL are different indicates differential regulation of each mucin.
We then sought to identify candidate genes for each QTL, initially using the QTL allele effects pattern as a way to identify potentially functionally distinct alleles at each locus and prioritize genes (Kelada et al. 2012) . For Muc5acq1, there were no obvious differences in phenotype among pre-CC mice categorized by most probable CC founder haplotype ( Figure S5 ). As such, we turned to other data to identify potential candidate genes for Muc5acq1. This locus contains 47 protein-coding genes and 50 noncoding RNAs. Expression data were available for 45 of the 47 protein-coding genes (based on GSE51768), and we assessed pairwise correlation of each gene with BALF MUC5AC. Eight genes were associated with MUC5AC at a nominal P-value threshold of 0.05 (Table S3 ). We also asked whether any of these genes had local eQTL using a previously generated eQTL data set from the same set of mice (Kelada et al. 2014) . Fifteen genes of the 47 had eQTL (Table S3 ). Finally, we conducted a literature search to see if any of the 47 genes had potential links to MUC5AC. In aggregate, no single gene stood out in terms of pairwise correlation and eQTL; however, evidence for biological plausibility for four genes (Slc9a3, Nr2f1, Glrx1, and Spata9) was obtained from the literature search. As such, these genes may be worthy of additional investigation in relation to MUC5AC.
In contrast to the allele effects for Muc5acq1, the allele effects for Muc5bq1 were striking. We found that alleles from A/J, NOD/ShiLtJ, and PWK/PhJ were associated with significantly lower levels of MUC5B ( Figure 2C ), indicating that these three alleles share functional similarities that result in low MUC5B BALF levels. Visualization of founder haplotypes based on high-density genotyping (Wang et al. 2012) in this region revealed that these three strains all share a Mus musculus musculus-derived haplotype spanning 152-154 Mb ( Figure S6 ), indicating intersubspecific introgression (Yang et al. 2011) of musculus haplotypes into the genomes of the A/J and NOD/ShiLtJ strains (classical inbred strains of domesticus origin). Using unbiased sequence data (Keane et al. 2011) , we constructed a phylogenetic tree for this region and confirmed that these three strains have musculusderived alleles that are distinct from all other CC founder strains ( Figure 2D ). This result indicates (based on parsimony) that the musculus haplotypes contain a functional variant (or variants) that cause lower MUC5B.
To prioritize candidate genes underlying the Muc5bq1, we could not rely on gene expression data for genes in this region because the microarray platform we used (Kelada et al. 2014) was based on C57BL/6J sequence and therefore was biased against M. m. musculus and castaneus transcripts emanating from Muc5bq1. We therefore chose to leverage other data sets to prioritize candidate genes. As described in the methods, we applied a weight of evidence approach to the gene list to prioritize genes based on expression in a relevant cell type (airway epithelia), change in expression in the lung due to allergen treatment, differences in expression in the lung due to subspecies origin, the presence of predicted amino acid variants shared by A/J, NOD/ShiLtJ, and PWK/PhJ founder strains, and previously published papers documenting a role for a gene in relevant biological pathways ( Figure S7 ). This approach identified Bpifb1 as a priority candidate gene because it met all of the aforementioned criteria.
Bpifb1 is a member of the BPI (bactericidal/permeabilityincreasing protein)/LBP (lipopolysaccharide-binding protein) family of lipid-transfer proteins, and was previously known as Lplunc1 for long palate lung and nasal epithelia clone (Bingle et al. 2011) . Previous studies in humans documented expression of BPIFB1 in goblet cells of the respiratory epithelium (Bingle et al. 2010) , secretion into the airways (Bingle et al. 2010; Gao et al. 2015) , and upregulation in CF (Bingle et al. 2012) and COPD (Gao et al. 2015; Titz et al. 2015) . In contrast, BPIFA1 is down-regulated in asthma models (Chu et al. 2007; Wu et al. 2017) .
To begin evaluating a potential role of Bpifb1 in MUC5B regulation, we examined lung gene expression in pre-CC mice followed by gene and protein expression in control and allergentreated inbred strains. For the pre-CC mice, we performed qRT-PCR with gene expression probes designed to avoid genetic variation in the CC founder genomes. We found that Muc5b and Bpifb1 mRNA were strongly and positively correlated among pre-CC mice (r = 0.75, P , 1 3 10 24 , Figure S8 ). This result prompted us to ask whether Muc5b and Bpifb1 were jointly upregulated in other mouse models of asthma. As shown in Table 1 , we found that expression of both Muc5b and Bpifb1 were nearly always increased in response to allergens such as ovalbumin, Alternaria, and HDM across three different inbred strains. Meta-analysis confirmed significant differential expression, with meta-analysis P-values of 1.5 3 10 213 and 1.8 3 10 210 for Muc5b and Bpifb1, respectively. Thus, this correlation appears to be generalizable to other mouse models of asthma. Lastly, we evaluated the correlation between MUC5B and BPIFB1 in C57BL/6J mice after sensitization and challenge with allergen or PBS (Figure 3) . We found that the expression of both proteins increased significantly as a function of allergen ( Figure 3B ) in a highly correlated fashion (r = 0.98, P , 0.001, Figure 3C ).
The strong correlations between Bpifb1 and Muc5b at the mRNA and protein level were potentially suggestive of a model in which the Chr 2 QTL leads to variation in Bpifp1 mRNA (i.e., is an eQTL), which in turn leads to variation in MUC5B protein levels. However, neither Bpifb1 nor Muc5b mRNAs were correlated with MUC5B protein levels in BALF in pre-CC mice ( Figure S9 ), ruling out the proposed eQTL-based model. Rather, our data suggest an alternative mechanism by which genetic variation in Bpifb1 affects MUC5B, potentially through amino acid variants that affect BPIFB1 protein structure/function. Musculus-derived haplotypes (i.e., A/J, NOD/ShiLtJ, and PWK/PhJ) associated with low MUC5B levels share the alternative allele of rs48926494, which encodes a valine to glycine substitution at amino acid 23 of BPIFB1. As such, this SNP is a potential causal variant.
Based on these results, we sought to further evaluate the role of Bpifb1 using knockout (KO) mice. Using qRT-PCR, we found that Bpifb1 mRNA was undetectable in KO mice (i.e., Ct values $ 38). To confirm the loss of expression of BPIFB1 protein in KO mice, we sensitized and challenged WT and KO mice with allergen to induce BPIFB1 protein expression and did not detect any BPIFB1 protein by immunohistochemistry in KO mice ( Figure S10 ).
We then measured secreted MUC5B in Bpifb1 WT and KO mice at baseline and after Der p 1 allergen sensitization and challenge with PBS or Der p 1 allergen ( Figure 4A ). Bpifb1 KO mice had a threefold increase in MUC5B in BALF under baseline conditions ("naïve" mice), which persisted after sensitization with allergen and challenge with PBS. After sensitization and allergen challenge, MUC5B in BALF increased proportionally in both genotypes. Thus our results indicate independent and additive effects for genotype and allergen treatment (i.e., no genotype by treatment interaction). MUC5AC was not affected by genotype in naïve or PBS-exposed mice and did increase after allergen challenge as expected, though the effect of genotype was not statistically significant ( Figure 4B) . Results from histological analysis of airway sections for luminal MUC5B content were consistent with BALF MUC5B data ( Figure 5 ). By quantitative morphometry, there was a significant increase in the fraction of intraluminal AB-PAS positive material in Bpifb1 KO mice and a matching trend for MUC5B ( Figure 5C ). Conversely, there was a trend toward decreased MUC5B intracellular staining in KO mice ( Figure S11 ). These differences were present despite roughly equal levels of airway inflammation as assessed by differential bronchoalveolar lavage cell counts ( Figure S12 ).
Discussion
We leveraged a series of genetic approaches, including an inbred strain survey, QTL mapping, and functional analysis of a candidate gene, to identify novel regulators of secreted mucin levels in the airways. Our initial studies involving the eight CC founder strains demonstrated that a large fraction of the variation in secreted MUC5AC and MUC5B was attributable to genetic differences between strains. Having established a genetic effect broadly, we turned to QTL mapping in the pre-CC population to identify the specific genetic loci that regulated these two secreted mucins. For the MUC5AC QTL (Muc5acq1), we identified potential candidate genes that merit exploration in future studies. Bpifb1 emerged as a priority candidate gene for the MUC5B QTL (Muc5bq1) based on a series of criteria, and we subsequently used Bpifb1 knockout mice to validate that BPIFB1 is causally related to levels of MUC5B levels in the airways.
Our ability to identify QTL and candidate genes was greatly facilitated by the use of the CC. In particular, the presence of musculus-derived alleles in the CC was beneficial in at least two ways. First, musculus-derived alleles were associated with lower MUC5B compared to domesticus-derived alleles, and because of the intersubspecific introgression (Yang et al. 2011) of musculus alleles into the genomes of the A/J and NOD/ShiLtJ founder strains, musculus-derived alleles were present in .30% of pre-CC mice. Second, the intersubspecific introgression of musculus alleles allowed us to narrow the MUC5B QTL from 7.5 to ,2 Mb. In terms of quantitative trait gene identification, these features complemented the already enhanced mapping resolution (7.5-10 Mb) in the CC compared to typical F2 intercrosses.
While we detected QTL for both MUC5AC and MUC5B that explain a relatively large fraction of phenotypic variance, our data indicate that there are additional QTL to identify. Indeed, the broad-sense heritability estimates based on CC founder strains were high, and the mucin phenotype distributions in the pre-CC population were consistent with a polygenic basis of inheritance. Future studies involving inbred CC strains, with biological replicates, will facilitate the identification of these additional loci. Study designs involving CC line intercrosses (recombinant inbred intercrosses) will also help explore the possibility of epistasis between loci, which was potentially suggested by the relatively large variance of MUC5B levels among pre-CC mice with the M. m. musculus-derived haplotype at the Chr 2 QTL.
The existence of distinct QTL for MUC5AC (Chr 13) and MUC5B (Chr 2) indicates that these mucins are under the control of distinct regulatory mechanisms in this model of muco-obstructive airway disease. Additionally, we found that while Muc5ac and Muc5b mRNA levels in the lung were strongly correlated, ostensibly due to shared transcriptional regulation, neither mRNA was correlated with the levels of secreted MUC5AC or MUC5B. Thus, our results highlight the existence of multiple regulatory pathways controlling the levels of mucins in the airway that could be affected by genetic variation. Given such complexity, it is perhaps not surprising that we identified trans-pQTL for both mucins. Consequently, we conclude that distal regulatory features separately control the levels of these two mucins in the airway. These results contrast with what is typically observed for eQTL detected under baseline conditions, which are often located close to genes, but are consistent with a recent study showing that trans-pQTL are abundant and often result from protein-protein interactions (Chick et al. 2016) . As such, we hypothesize that there may be protein-protein interactions underlying the observed relationship between MUC5B and BPIFB1. In addition to the observed strong correlation of MUC5B and BPIFB1 in the airways of allergen-challenged mice, which is suggestive of protein colocalization, BPIFB1 has been shown to have strong interactions with mucins in human bronchial epithelial cell secretions (Radicioni et al. 2016) , supporting this hypothesis. Furthermore, we can rule out the possibility that variation in Bpifb1 gene expression underlies the QTL since Bpifb1 mRNA was not correlated with secreted MUC5B.
Previous studies have provided evidence that BPIFB1 is involved in human airway diseases in which MUC5B is upregulated, including CF (Scheetz et al. 2004; Bingle et al. 2012) and COPD (Gao et al. 2015; Titz et al. 2015) , as well as IPF (Yang et al. 2013; Gao et al. 2015) . Data for the role of BPIFB1 in asthma are more sparse, but upregulation has been observed in a study involving segmental allergen challenge (Wu et al. 2005) . There are conflicting reports of how MUC5B levels change in asthma, with reports of increased MUC5B in spontaneous sputum and asthmatic plugs (Groneberg et al. 2002; Kirkham et al. 2002) contrasting with a report of decreased MUC5B in induced sputum (Lachowicz-Scroggins et al. 2016) . A very recent report linked differences in the glycosylation status of MUC5B to asthma exacerbations ( Welsh et al. 2017) . We note that while some studies have reported decreased MUC5B in asthma, antibody-based approaches may be biased due to protein degradation that can occur in the context of inflamed or infected airways (Henderson et al. 2014 ). This does not appear to have biased our results, though, as we detected differences in MUC5B in Bpifb1 KO mice compared to WT mice under baseline conditions. However, quantification by mass spectrometry will be necessary to measure the levels of MUC5B in a completely unbiased manner. Nevertheless, the body of evidence that MUC5B and BPIFB1 are upregulated in different airway diseases suggests that the association between BPIFB1 and MUC5B may be a common feature of obstructive lung diseases in which MUC5B is elevated. Additionally, we showed that this correlation is present at the level of gene expression in multiple mouse models of asthma and at the protein level upon allergen challenge. Our data provide clear evidence that BPIFB1 is causally related to MUC5B BALF levels. A rather simple hypothesis to put forth is that BPIFB1 regulates some aspect (s) of MUC5B accumulation in the airways. Indeed, we found evidence of an increase in the fraction of AB-PAS positive luminal substance in Bpifb1 KO mice whereas the total histological signal in the airways was not affected by genotype. There are at least two possible mechanisms that can explain our observations of higher MUC5B levels in the Bpifb1 KO strain, namely enhanced secretion into the airways or reduced clearance from the airways. Given that there is already evidence that BPIFB1 and MUC5B interact (Radicioni et al. 2016) , it will be important to investigate how these interactions affect secretion and/or clearance in future studies. It is interesting to note that in contrast to Bpifb1 KO mice, which had high MUC5B levels, pre-CC mice with the musculus haplotype of Bpifb1 had lower levels of MUC5B. Thus, the putative causal variant we identified (rs48926494) could impair secretion or facilitate clearance. The use of models that can produce either high or low MUC5B in the airways as a function of Bpifb1 genotype will be an asset to the investigation of mucus accumulation driven by the interactions between these two proteins.
In summary, through our unbiased, genome-wide search, we have identified distinct loci that regulate MUC5AC and MUC5B levels in the airway after allergen sensitization and challenge. We identified Bpifb1 as a candidate gene for the MUC5B QTL, and confirmed a causal role for this gene in regulating the levels of secreted MUC5B in the airways, a phenotype that contributes to airway defense and multiple airways diseases. 
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